News

Methotrexate ups risk of liver abnormalities, but not serious hepatic events


 

FROM SEMINARS IN ARTHRITIS AND RHEUMATISM

References

Methotrexate use more than doubled the risk of liver enzyme abnormalities but was not tied to serious hepatic outcomes among patients with rheumatic diseases, according to a meta-analysis of 32 randomized, controlled trials.

“Serious liver events were rare, with a suggestion of a trend towards fewer poor liver outcomes,” wrote Dr. Richard Conway of Galway (Ireland) University Hospitals. “The short duration of the included studies and the lack of liver biopsies are limitations, but the available data provide robust evidence for short-term safety” of methotrexate, wrote Dr. Conway and his associates.

Methotrexate is a first-line RA therapy with efficacy in several other inflammatory diseases, but concerns about toxicity have limited its use, the researchers noted. Clinicians have particularly debated its hepatic effects, in part because it can be “exceedingly difficult” to determine if liver disease is preexisting, methotrexate related, or caused by other medications or comorbidities, they said. To better assess the issue, they searched PubMed and the Cochrane Central Register of Controlled Trials for relevant double-blind, randomized, controlled trials published between 1990 and 2014. They found 32 such trials that included 13,177 patients with rheumatoid arthritis, psoriasis, psoriatic arthritis or inflammatory bowel disease (Semin Arthritis Rheum. 2015;45:156-62). Methotrexate use approximately doubled the risk of any adverse hepatic event (relative risk, 2.19; 95% confidence interval, 1.73-2.77) and of major and minor liver enzyme abnormalities (RR, 2.16; 95% CI, 1.67-2.79), but did not increase the risk of liver failure, cirrhosis, or liver-related mortality (RR, 0.12; 95% CI, 0.01-1.09), the investigators reported. “Clinical trials have inherent limitations, including short duration, selection bias, failure to collect information or reports that are not part of a prespecified protocol, and limited power to evaluate rare or unusual reports,” they cautioned. “While meta-analyses help overcome the last of these, the others raise some concern.”

But several other reports align with their results, the researchers noted. In an analysis of methotrexate studies lasting at least 2 years, about 10% of patients developed at least one minor liver enzyme abnormality, but less than 4% stopped methotrexate because of liver toxicity. Other controlled studies did not link methotrexate to severe fibrosis or cirrhosis – even after 4 years of treatment, they added. “It appears likely that serious liver-related complications due to methotrexate may take many years of treatment to manifest,” the investigators concluded.

The researchers reported no funding sources or conflicts of interest.

Recommended Reading

Yet another insurer demand: patient care notifications
MDedge Internal Medicine
Predictors identified for progression of moderate RA on methotrexate
MDedge Internal Medicine
OCs may ease inflammatory arthritis severity
MDedge Internal Medicine
Long-term RA remission can restore physical function
MDedge Internal Medicine
Tofacitinib proves effective in RA when biologics don’t work
MDedge Internal Medicine
New IPF guidelines limit treatment choices
MDedge Internal Medicine
ESC: Celecoxib safety study may soothe cardio concerns
MDedge Internal Medicine
VIDEO: Use fiduciary duty to set pain medication boundaries
MDedge Internal Medicine
Infliximab biosimilar SB2 shows efficacy, safety similar to Remicade for RA
MDedge Internal Medicine
Biomarker test couldn’t predict RA transformation from undifferentiated arthritis
MDedge Internal Medicine